Cardiac Biomarkers Testing Global Market Report 2024

The cardiac biomarkers testing market size has grown rapidly in recent years. It will grow from $12.15 billion in 2023 to $13.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period of cardiac biomarkers testing can be attributed to various factors including a rise in cardiovascular diseases, an aging population, increased awareness through educational initiatives, supportive government policies, and a general uptick in healthcare expenditure. These elements collectively contributed to the expansion and adoption of cardiac biomarker tests.

The cardiac biomarkers testing market size is expected to see rapid growth in the next few years. It will grow to $21.31 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. In the forthcoming period, the growth of cardiac biomarkers testing is expected due to the emergence of personalized medicine, a worldwide increase in cardiovascular diseases, the incorporation of artificial intelligence (AI) into diagnostics, the widening scope of point-of-care testing (POCT), and a greater focus on early disease detection. Key trends anticipated in this period encompass technological advancements, the evolution of AI-assisted diagnostics, the expansion of point-of-care testing (POCT), the enhancement of multiplexing capabilities, and ongoing efforts in biomarker discovery and validation.

The anticipated rise in the prevalence of cardiovascular diseases is poised to drive the growth of the cardiac biomarkers testing market. Cardiovascular diseases, impacting the heart or blood vessels, necessitate quick and accurate diagnostic tools. Cardiac biomarker tests play a crucial role by assessing biomarker levels to promptly determine the severity and magnitude of a heart attack. As indicated by data from the American College of Cardiology in August 2022, the United States is expected to witness a considerable increase in the rates of cardiovascular risk factors and diseases by the year 2060. This projection underscores the anticipated surge in demand for cardiac biomarker testing solutions, aligning with the overall growth of the cardiac biomarkers testing market.

The growing demand for personalized medical solutions emerges as a significant driver propelling the cardiac biomarkers testing market forward. Personalized medicine, tailoring medical decisions and interventions to individual patients, is increasingly incorporating cardiac biomarkers testing for more precise cardiovascular care. This integration enhances prevention, early detection, and treatment strategies, addressing the specific needs of each patient. Notably, reports from October 2022 indicate a significant presence of over 75,000 genetic testing products and 300 personalized medicines, reflecting the expanding demand for personalized medicine solutions. This trend contributes to the sustained growth of the cardiac biomarkers testing market.

Product innovations stand out as a key trend within the cardiac biomarkers testing market, with major companies prioritizing the development of innovative solutions to maintain their market positions. Siemens Healthcare GmbH, a Germany-based medical technology company, exemplified this trend in October 2021 with the launch of the Atellica VTLi Patient-Side Immunoassay Analyzer. Distinguished by its high-sensitivity troponin I test from a fingerstick sample, this analyzer enables clinicians and healthcare professionals to diagnose a heart attack rapidly and reliably in just eight minutes. The introduction of such innovative products underscores the industry's commitment to advancing diagnostic capabilities and improving patient outcomes in the cardiac biomarkers testing market.

Prominent companies in the cardiac biomarker testing market are strategically focusing on innovative products, with a particular emphasis on cardiac biomarkers, to drive revenue growth. Cardiac biomarkers, also referred to as cardiac enzymes, are substances released into the bloodstream in response to heart muscle damage, serving as crucial indicators in diagnosing and monitoring cardiovascular conditions. In October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a China-based company specializing in medical equipment and solutions, launched troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTn assay surpasses minimal requirements for sensitivity, accuracy, and reliability in identifying myocardial damage. These innovative products aim to enhance treatment for cardiovascular illnesses, providing reliable solutions that improve patient outcomes both within and beyond the realm of cardiovascular diseases.

In September 2021 , Shenzhen Mindray Bio-Medical Electronics Co. Ltd executed the acquisition of HyTest Invest Oy and its subsidiaries, including HyTest Ltd, for an undisclosed amount. HyTest, a US-based provider of antibodies and antigens with a focus on the In Vitro Diagnostics (IVD) market, brings valuable expertise in cardiac indicators, inflammation, tumor markers, and other diagnostic areas. This acquisition enhances Mindray's research and development (R&D) capabilities for raw materials, reinforcing its commitment to innovation. It positions HyTest to maintain its status as a world leader in the upstream IVD raw material industry by supporting continued investment in R&D and strengthening its core competitive edge. The strategic acquisition aligns with the industry trend of enhancing capabilities and expanding product portfolios to meet evolving demands in the cardiac biomarker testing market.

Major companies operating in the cardiac biomarkers testing market report are Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation.

North America was the largest region in the cardiac biomarkers testing market in 2023. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac biomarkers testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key biomarkers in cardiac biomarkers testing include creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), and various others. Creatine kinase (CK-MB) is an enzyme analyzed through a blood test. These tests find applications in conditions such as congestive heart failure, acute coronary syndrome, myocardial infarction, atherosclerosis, among others, primarily utilized by hospitals and specialized clinics.

The cardiac biomarkers testing market research report is one of a series of new reports that provides cardiac biomarkers testing market statistics, including cardiac biomarkers testing industry global market size, regional shares, competitors with cardiac biomarkers testing market share, detailed cardiac biomarkers testing market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac biomarkers testing industry. This cardiac biomarkers testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.